{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:08:54Z","timestamp":1789434534301,"version":"build-2803163510"},"reference-count":34,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The Second Revision of the International Staging System (R2-ISS) was published in 2022 and has been validated in several cohorts of patients with multiple myeloma (MM). In this study, we investigated a total of 860 patients with MM who received an upfront autologous stem cell transplantation between 2001 and 2021. The median age of the patients was 60 years, with a median overall survival (OS) of 123\u00a0months and median progression-free survival (PFS) of 70\u00a0months. We collected the variables included in the ISS, R-ISS, and R2-ISS systems as well as additional standard variables. Our analyses demonstrated that all 3 ISS series systems (ISS, R-ISS, and R2-ISS) exhibited robust discrimination in terms of both OS and PFS among our study cohort. The ISS system effectively stratified patients into 3 risk groups, whereas the R-ISS system accurately identified patients at extremely high or low risk. The R2-ISS system further refined risk stratification by dividing patients into 4 more balanced risk groups. Furthermore, we specifically focused on identifying variables that distinguished patients with OS\u00a0&amp;lt; 3 years and OS &amp;gt; 10 years within the low-risk R2-ISS stages (I and II) and high-risk R2-ISS stages (III and IV). Our findings revealed that age, hemoglobin, and 1p deletion significantly influenced the classification of patients in the low-risk R2-ISS stage. Additionally, serum light chain, platelet count, age, and the presence of the t(14;16) translocation were found to affect high-risk classification.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023011096","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T15:11:40Z","timestamp":1695827500000},"page":"6676-6684","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS"],"prefix":"10.1182","volume":"7","author":[{"given":"Wancheng","family":"Guo","sequence":"first","affiliation":[{"name":"1Myeloma Center, Winthrope P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"},{"name":"2Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Zhan","sequence":"additional","affiliation":[{"name":"3Little Rock Central High School, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-9777","authenticated-orcid":false,"given":"David E.","family":"Mery","sequence":"additional","affiliation":[{"name":"1Myeloma Center, Winthrope P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manit N.","family":"Munshi","sequence":"additional","affiliation":[{"name":"4College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oussama","family":"Makhoul","sequence":"additional","affiliation":[{"name":"4College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3694-0797","authenticated-orcid":false,"given":"Clyde","family":"Baily","sequence":"additional","affiliation":[{"name":"1Myeloma Center, Winthrope P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[{"name":"1Myeloma Center, Winthrope P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Tricot","sequence":"additional","affiliation":[{"name":"1Myeloma Center, Winthrope P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Peng","sequence":"additional","affiliation":[{"name":"2Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"John D.","family":"Shaughnessy","sequence":"additional","affiliation":[{"name":"1Myeloma Center, Winthrope P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"issue":"5","key":"2023111415004394100_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","article-title":"High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions","volume":"12","author":"Hagen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"15","key":"2023111415004394100_bib2","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2023111415004394100_bib3","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"29","key":"2023111415004394100_bib4","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY Project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023111415004394100_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hon.3090","article-title":"The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor-based regimens as induction treatment: a real-world analysis","volume":"41","author":"Chen","year":"2023","journal-title":"Hematol Oncol"},{"issue":"2","key":"2023111415004394100_bib6","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1111\/bjh.18536","article-title":"The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: real world data results in an Australian and New Zealand population","volume":"200","author":"Tan","year":"2023","journal-title":"Br J Haematol"},{"issue":"6","key":"2023111415004394100_bib7","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00259-022-06088-x","article-title":"A\u00a0prognostication system based on clinical parameters and [(18)F]-FDG PET\/CT in patients with newly diagnosed multiple myeloma","volume":"50","author":"Li","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2023111415004394100_bib8","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s12185-023-03541-x","article-title":"Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice","volume":"117","author":"Mizuguchi","year":"2023","journal-title":"Int J Hematol"},{"key":"2023111415004394100_bib9","doi-asserted-by":"crossref","first-page":"107037","DOI":"10.1016\/j.leukres.2023.107037","article-title":"Evaluation of the simplified score to predict early relapse in multiple myeloma (S-ERMM) in the MMRF CoMMpass study","volume":"127","author":"Slade","year":"2023","journal-title":"Leuk Res"},{"issue":"4","key":"2023111415004394100_bib10","doi-asserted-by":"crossref","first-page":"e857","DOI":"10.1097\/HS9.0000000000000857","article-title":"The R2-ISS in a multicenter cohort of chinese patients with newly diagnosed multiple myeloma","volume":"7","author":"Yang","year":"2023","journal-title":"Hemasphere"},{"issue":"14","key":"2023111415004394100_bib11","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1097\/CM9.0000000000002735","article-title":"Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma","volume":"136","author":"Yan","year":"2023","journal-title":"Chin Med J"},{"issue":"19","key":"2023111415004394100_bib12","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023111415004394100_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A\u00a0prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"36","key":"2023111415004394100_bib14","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023111415004394100_bib15","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blade","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2023111415004394100_bib16","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2023111415004394100_bib17","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1182\/blood-2002-09-2873","article-title":"Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression","volume":"101","author":"Shaughnessy","year":"2003","journal-title":"Blood"},{"issue":"10","key":"2023111415004394100_bib18","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1182\/blood-2007-10-119123","article-title":"An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma","volume":"112","author":"Xiong","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2023111415004394100_bib19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2004-04-1363","article-title":"p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation","volume":"105","author":"Chang","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2023111415004394100_bib20","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2023111415004394100_bib21","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood.V99.5.1745","article-title":"Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells","volume":"99","author":"Zhan","year":"2002","journal-title":"Blood"},{"issue":"24","key":"2023111415004394100_bib22","doi-asserted-by":"crossref","first-page":"484","DOI":"10.21037\/atm.2017.09.39","article-title":"Comparing baseline characteristics between groups: an introduction to the CBCgrps package","volume":"5","author":"Zhang","year":"2017","journal-title":"Ann Transl Med"},{"issue":"3","key":"2023111415004394100_bib23","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A\u00a0clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"issue":"21","key":"2023111415004394100_bib24","doi-asserted-by":"crossref","first-page":"12070","DOI":"10.3390\/ijms222112070","article-title":"The significance of mRNA in the biology of multiple myeloma and its clinical implications","volume":"22","author":"Pu\u0142a","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2023111415004394100_bib25","doi-asserted-by":"crossref","first-page":"e0278464","DOI":"10.1371\/journal.pone.0278464","article-title":"Serum proteomic profiling reveals MTA2 and AGO2 as potential prognostic biomarkers associated with disease activity and adverse outcomes in multiple myeloma","volume":"17","author":"Apipongrat","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"2023111415004394100_bib26","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/jha2.276","article-title":"Validation of clinical-grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newly-diagnosed multiple myeloma patients: a pilot study from the 100,000 Genomes Project","volume":"2","author":"Lomas","year":"2021","journal-title":"EJHaem"},{"issue":"3","key":"2023111415004394100_bib27","doi-asserted-by":"crossref","first-page":"e757","DOI":"10.1002\/ctm2.757","article-title":"Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma","volume":"12","author":"He","year":"2022","journal-title":"Clin Transl Med"},{"issue":"6","key":"2023111415004394100_bib28","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A\u00a0validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"issue":"13","key":"2023111415004394100_bib29","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1182\/blood-2010-12-328252","article-title":"Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3","volume":"118","author":"Shaughnessy","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2023111415004394100_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2010.030296","article-title":"Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma","volume":"96","author":"Hose","year":"2011","journal-title":"Haematologica"},{"issue":"11","key":"2023111415004394100_bib31","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/leu.2012.127","article-title":"A\u00a0gene expression signature for high-risk multiple myeloma","volume":"26","author":"Kuiper","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"2023111415004394100_bib32","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.30526","article-title":"Racial disparities in treatment use for multiple myeloma","volume":"123","author":"Fiala","year":"2017","journal-title":"Cancer"},{"issue":"12","key":"2023111415004394100_bib33","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/cam4.1246","article-title":"Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis","volume":"6","author":"Ailawadhi","year":"2017","journal-title":"Cancer Med"},{"issue":"6","key":"2023111415004394100_bib34","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/bloodadvances.2021005482","article-title":"Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials","volume":"6","author":"Kanapuru","year":"2022","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6676\/2089239\/blooda_adv-2023-011096-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6676\/2089239\/blooda_adv-2023-011096-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:07:19Z","timestamp":1699956439000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/21\/6676\/498127\/Application-of-R2-ISS-risk-stratification-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":34,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,11,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011096","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}